AIM
NKTR icon

Allen Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Allen Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,424
Closed -$760K – 197
2019
Q2 		$760K Hold
1,424
– – 0.02% 121
2019
Q1 		$718K Buy
+1,424
New +$844K 0.02% 118
2018
Q4 		– Sell
-1,547
Closed -$1.42M – 177
2018
Q3 		$1.42M Hold
1,547
– – 0.05% 100
2018
Q2 		$1.13M Hold
1,547
– – 0.04% 99
2018
Q1 		$2.47M Buy
+1,547
New +$1.99M 0.1% 70

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allen Investment Management's NKTR Position: Q3 2019 in Review

Allen Investment Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 1,424 shares — an estimated $760K sold.

Allen Investment Management first reported a position in NKTR in Q1 2018 and held it in 5 quarters. The position peaked at $2.47M in Q1 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Allen Investment Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Allen Investment Management sold 1,424 Nektar Therapeutics shares in Q3 2019, an estimated $760K.
  • Allen Investment Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 5 quarters.
  • Allen Investment Management's Nektar Therapeutics position peaked at $2.47M in Q1 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Allen Investment Management's 13F filing for Q3 2019, filed 6 Nov 2019.